Welcome to our dedicated page for TEVA PHARMACEUTICAL INDUSTRIES SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TEVA PHARMACEUTICAL INDUSTRIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TEVA PHARMACEUTICAL INDUSTRIES's regulatory disclosures and financial reporting.
Satchi-Fainaro Ronit reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director RSU grant: Director Ronit Satchi-Fainaro received 7,242 restricted share units as a compensation award. Each unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one share. The award was granted on May 28, 2026 and will vest on May 28, 2027, subject to the plan’s conditions. Following this grant, the director holds 7,242 RSUs directly, and these may be settled in ordinary shares, which can be represented by American Depositary Shares on a 1:1 basis.
Nisen Perry reported acquisition or exercise transactions in this Form 4 filing.
Teva Pharmaceutical Industries director Nisen Perry received a grant of 7,242 restricted share units. The award was granted on May 28, 2026 and will fully vest on May 28, 2027. Each restricted share unit gives a contingent right to one ordinary share or, at the committee’s option, the cash value of one ordinary share, which may be represented by American Depositary Shares.
LIEBERMAN GERALD M reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Gerald M. Lieberman reported a compensation grant of restricted share units. On May 28, 2026, he received 7,242 restricted share units, each linked to one ordinary share. These units vest on May 28, 2027, and he now holds 7,242 units directly.
Each unit represents a contingent right to receive either one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. The ordinary shares may be represented by American Depositary Shares, with each ADS currently equal to one ordinary share.
Elstein Amir reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Amir Elstein received a grant of 7,242 restricted share units. These units were awarded on May 28, 2026 and will vest on May 28, 2027. Each unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
After this grant, Elstein holds 7,242 restricted share units directly. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
Crane Rosemary A reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Rosemary A. Crane received a grant of 7,242 restricted share units as equity compensation. These restricted share units were awarded on May 28, 2026 and will vest on May 28, 2027, meaning she must remain eligible through that date to receive the shares.
Each restricted share unit represents a contingent right to receive one ordinary share of Teva, or at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. The ordinary shares may be represented by American Depositary Shares, with each ADS currently equal to one ordinary share. Following this award, Crane directly holds 7,242 restricted share units related to Teva ordinary shares.
Lichtenstein Chen reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Lichtenstein Chen received a grant of 7,242 Restricted Share Units (RSUs). These RSUs were granted on May 28, 2026 and are scheduled to vest on May 28, 2027, functioning as part of equity-based compensation.
Each RSU represents a contingent right to receive, at settlement, either one ordinary share or the cash value of one ordinary share, at the option of the Human Resources and Compensation Committee. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
BARER SOL J reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Sol J. Barer received a grant of restricted share units. On May 28, 2026, Barer was awarded 10,863 restricted share units, each representing a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The units vest on May 28, 2027, and are reported as a direct holding. Following this grant, Barer holds 10,863 restricted share units linked to the company’s ordinary shares, which may also be represented by American Depositary Shares on a one-for-one basis.
MIGNONE ROBERTO reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Roberto Mignone received a grant of 7,242 restricted share units on May 28, 2026. Each restricted share unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The restricted share units vest on May 28, 2027, and are reported as directly owned. Following this award, Mignone’s reported holding of restricted share units is 7,242. The ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
Teva Pharmaceutical Industries Limited reported results of its annual shareholder meeting held on May 28, 2026. Shareholders elected Dr. Sol J. Barer to the Board to serve until the 2029 annual meeting, with 627,816,662 votes for and 245,921,571 against.
Shareholders also approved, on a non-binding advisory basis, the compensation of Teva’s named executive officers, with 795,976,042 votes for and 77,082,847 against. In addition, they approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as independent registered public accounting firm through the 2027 annual meeting.
TEVA PHARMACEUTICAL INDUSTRIES LTD EVP, Business Development Evan Lippman reported an exercise-and-sell transaction in company stock. On May 14, 2026, he exercised restricted share units to acquire 85,849 Ordinary Shares at a conversion price of $0.00 per share.
On the same date, he sold a total of 41,658 Ordinary Shares at a weighted average price of $35.5842 per share, with individual sale prices ranging from $35.38 to $35.685. A footnote states that a portion of the sold shares was required to cover tax withholding obligations related to the RSU vesting, and that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan.